Tamiflu Vaccine Linked With Convulsions, Delirium and Bizarre Deaths

[Pastor Dale Morgan]

*Plagues, Pestilences and Diseases

Tamiflu Vaccine Linked With Convulsions, Delirium and Bizarre Deaths*

by David Gutierrez

(NaturalNews) An FDA advisory panel has recommended stronger warnings on
two influenza drugs after reviewing evidence linking them to
neurological and psychiatric problems that have led to deaths in some cases.

The current warning on Roche Laboratories' Tamiflu (generic name
oseltamivir) urges close monitoring of flu patients, particularly
children, for "increased risk of self injury and confusion shortly after
taking Tamiflu." The panel recommended that this warning be strengthened
to say that "in some cases, these behaviors resulted in serious
injuries, including death, in adult and pediatric patients."

The label of Glaxo SmithKline's Relenza (generic name zanamivir), the
panel said, should be strengthened to mention "reports of
hallucinations, delirium and abnormal behavior." The panel said that
both labels should mention that some flu patients not taking the drugs
have also experienced such symptoms.

There have been no reported deaths from Tamiflu in the United States,
but in Japan, where the drug is much more widely used, at least 14
deaths have been reported. Five children under the age of 17 died after
"falling from windows or balconies or running into traffic," according
to the FDA. According to Roche, two people under the age of 21 died from
a brain infection, and seven deaths from neuropsychiatric symptoms have
also been attributed to use of the drug by adults.

Since Tamiflu's introduction in 1999, a total of 48 million
prescriptions have been written, 75 percent of them in Japan. According
to Roche, 1,745 of 1,808 reports of side effects came from Japan.

The FDA has noted that people in Japan appear to be more likely to
report side effects than people in the United States.

In March, Japan issued a warning against prescribing Tamiflu to people
between the ages of 10 and 19, and South Korea followed suit a month
later with a warning against use by teenagers.